PAP for Children With DS and OSAS

Sponsor
Children's Hospital of Philadelphia (Other)
Overall Status
Recruiting
CT.gov ID
NCT04132999
Collaborator
National Institutes of Health (NIH) (NIH), National Heart, Lung, and Blood Institute (NHLBI) (NIH), Children's Hospital Medical Center, Cincinnati (Other), University of Pennsylvania (Other)
86
2
2
42.1
43
1

Study Details

Study Description

Brief Summary

Determine the efficacy of family-informed intervention (INT) vs standard clinical care over a period of twelve months in children with obstructive sleep apnea and Down Syndrome.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Family-informed intervention
  • Behavioral: Standard Clinical Care
N/A

Detailed Description

Evaluate the effect of PAP adherence on quality of life, neurobehavioral, and healthcare utilization in children with DS and OSAS. It is being hypothesized that, irrespective of study arm, increased PAP adherence will be associated with better quality of life, neurobehavioral, and healthcare utilization outcomes.

Evaluate the effect of PAP adherence in children with DS and OSAS on patient-centered outcomes and family-relevant outcomes identified during the R61 phase of this research. It is being hypothesized that irrespective of study arm, increased PAP adherence will be associated with better patient-centered outcomes, and family-relevant outcomes identified during the first year of this research.

Determine the efficacy of INT vs. CON in promoting PAP adherence. It is being hypothesized that that children receiving INT will show significantly increased objectively-measured PAP adherence at 6 months compared with those receiving CON (Aim 4A). As a secondary aim (4B), it will be evaluated whether the improved adherence is maintained over 12 months. It is being hypothesized that participants initially randomized to the INT arm will have better adherence at 12 months compared to those in the CON arm.

Use mixed methods during the randomized controlled trial to identify family perceptions, such as empowerment and self-efficacy, regarding PAP use in youth with OSAS and DS. It is being hypothesized that INT-PAP will be associated with more positive perceptions compared to CON.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
86 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
family-informed intervention (INT) vs standard clinical care (CON).family-informed intervention (INT) vs standard clinical care (CON).
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
Positive Airway Pressure for the Treatment of the Obstructive Sleep Apnea Syndrome in Children With Down Syndrome (Stage 2)
Actual Study Start Date :
Mar 1, 2021
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Family-informed intervention (INT)

Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team.

Behavioral: Family-informed intervention
Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team

Active Comparator: Standard Clinical Care

Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.

Behavioral: Standard Clinical Care
Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.

Outcome Measures

Primary Outcome Measures

  1. Effect of PAP adherence on quality of life and neurobehavioral outcomes [Baseline, 6 months, and 12 months]

    PedsQL score and measures of executive functioning will be compared in the 2 groups. PedsQL is a 5-point scale ranging from 0-4 (0 = Never, 4 = Always).

  2. Efficacy of INT-PAP in promoting PAP adherence [6 months, and 12 months]

    Adherence to PAP expressed as percentage of nights used, and minutes of usage on nights used.

  3. Efficacy of CON in promoting PAP adherence [6 months, and 12 months]

    Adherence to PAP expressed as percentage of nights used, and minutes of usage on nights used.

  4. Effect of PAP adherence in children with DS and OSAS on patient-centered outcomes and family-relevant outcomes identified during the R61 phase of this research [Baseline, 6 months, and 12 months]

    Patient-centered outcomes and family-relevant outcomes - identified during the R61 phase of the study (Stage 1) - will be compared between the intervention and control groups. These are qualitative measures, and require interviews and further analysis to be established.

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical referral for PAP initiation to treat OSAS

  • Ages 6-18 years

  • Children are able to cooperate with testing

  • Naive to PAP treatment

Exclusion Criteria:
  • Major illnesses, such as leukemia or severe cyanotic congenital heart disease listed for cardiac transplant.

  • Family planning to move out of the city within the next year

  • Children in foster care

  • Child with previously treated with PAP

  • Caregivers who do not speak English well enough to complete behavioral and performance measures.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cincinnati Children's Hospital Medical Center Cincinnati Ohio United States 45229
2 The Children's Hospital of Philadelphia Philadelphia Pennsylvania United States 19104

Sponsors and Collaborators

  • Children's Hospital of Philadelphia
  • National Institutes of Health (NIH)
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Children's Hospital Medical Center, Cincinnati
  • University of Pennsylvania

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:
NCT04132999
Other Study ID Numbers:
  • 20-017512
  • R61HL151253-01
First Posted:
Oct 21, 2019
Last Update Posted:
Mar 16, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Children's Hospital of Philadelphia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 16, 2022